A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation

Immunity

Volumn 20, Issue 4, 2004, Pages 495-506

  Reits, Eric ^a   Neijssen, Joost ^a   Herberts, Carla ^a   Benckhuijsen, Willemien ^b   Janssen, Lennert ^a   Drijfhout, Jan Wouter ^b   Neefjes, Jacques ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDASE; PEPTIDASE TPPII; PROTEASOME; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIGEN PRESENTATION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVITY; HALF LIFE TIME; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; BLOTTING, WESTERN; CELL LINE; CYSTEINE ENDOPEPTIDASES; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MULTIENZYME COMPLEXES; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; SERINE ENDOPEPTIDASES; SUBSTRATE SPECIFICITY;

EID: 1842785206     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(04)00074-3     Document Type: Article

References (42)

1. Agami R., Bernards R. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell. 102:2000;55-66.
2. Beninga J., Rock K.L., Goldberg A.L. Interferon-gamma can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase. J. Biol. Chem. 273:1998;18734-18742.
3. Breslin H.J., Miskowski T.A., Kukla M.J., Leister W.H., De Winter H.L., Gauthier D.A., Somers M.V., Peeters D.C., Roevens P.W. Design, synthesis, and tripeptidyl peptidase II inhibitory activity of a novel series of (S)-2,3-dihydro-2-(4-alkyl-1H-imidazol-2-yl)-1H-indoles. J. Med. Chem. 45:2002;5303-5310.
4. Bromme D., Rossi A.B., Smeekens S.P., Anderson D.C., Payan D.G. Human bleomycin hydrolase. molecular cloning, sequencing, functional expression, and enzymatic characterization Biochemistry. 35:1996;6706-6714.
5. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 296:2002;550-553.
6. Cascio P., Hilton C., Kisselev A.F., Rock K.L., Goldberg A.L. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J. 20:2001;2357-2366.
7. Fruci D., Lauvau G., Saveanu L., Amicosante M., Butler R.H., Polack A., Ginhoux F., Lemonnier F., Firat H., van Endert P.M. Quantifying recruitment of cytosolic peptides for HLA class I presentation. impact of TAP transport J. Immunol. 170:2003;2977-2984.
8. Ganellin C.R., Bishop P.B., Bambal R.B., Chan S.M., Law J.K., Marabout B., Luthra P.M., Moore A.N., Peschard O., Bourgeat P.et al. Inhibitors of tripeptidyl peptidase II. 2. Generation of the first novel lead inhibitor of cholecystokinin-8-inactivating peptidase. a strategy for the design of peptidase inhibitors J. Med. Chem. 43:2000;664-674.
9. Geier E., Pfeifer G., Wilm M., Lucchiari-Hartz M., Baumeister W., Eichmann K., Niedermann G. A giant protease with potential to substitute for some functions of the proteasome. Science. 283:1999;978-981.
10. Glas R., Bogyo M., McMaster J.S., Gaczynska M., Ploegh H.L. A proteolytic system that compensates for loss of proteasome function. Nature. 392:1998;618-622.
11. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway. destruction for the sake of construction Physiol. Rev. 82:2002;373-428.
12. Johnson G.D., Hersh L.B. Studies on the subsite specificity of the rat brain puromycin-sensitive aminopeptidase. Arch. Biochem. Biophys. 276:1990;305-309.
13. Kisselev A.F., Akopian T.N., Woo K.M., Goldberg A.L. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J. Biol. Chem. 274:1999;3363-3371.
14. Kloetzel P.M. Antigen processing by the proteasome. Nat. Rev. Mol. Cell Biol. 2:2001;179-187.
15. Koopmann J.O., Post M., Neefjes J.J., Hammerling G.J., Momburg F. Translocation of long peptides by transporters associated with antigen processing (TAP). Eur. J. Immunol. 26:1996;1720-1728.
16. Koopmann J.O., Albring J., Huter E., Bulbuc N., Spee P., Neefjes J., Hammerling G.J., Momburg F. Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. Immunity. 13:2000;117-127.
17. Mo X.Y., Cascio P., Lemerise K., Goldberg A.L., Rock K. Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides. J. Immunol. 163:1999;5851-5859.
18. Momburg F., Roelse J., Hammerling G.J., Neefjes J.J. Peptide size selection by the major histocompatibility complex-encoded peptide transporter. J. Exp. Med. 179:1994;1613-1623. a.
19. Momburg F., Roelse J., Howard J.C., Butcher G.W., Hammerling G.J., Neefjes J.J. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature. 367:1994;648-651. b.
20. Princiotta M.F., Schubert U., Chen W., Bennink J.R., Myung J., Crews C.M., Yewdell J.W. Cells adapted to the proteasome inhibitor 4-hydroxy-5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival. Proc. Natl. Acad. Sci. USA. 98:2001;513-518.
21. Princiotta M.F., Finzi D., Qian S.B., Gibbs J., Schuchmann S., Buttgereit F., Bennink J.R., Yewdell J.W. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity. 18:2003;343-354.
22. Rammensee H.G., Falk K., Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 11:1993;213-244.
23. Reits E.A., Vos J.C., Gromme M., Neefjes J. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature. 404:2000;774-778.
24. Reits E., Griekspoor A., Neijssen J., Groothuis T., Jalink K., van Veelen P., Janssen H., Calafat J., Drijfhout J.W., Neefjes J. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity. 18:2003;97-108.
25. Renn S.C., Tomkinson B., Taghert P.H. Characterization and cloning of tripeptidyl peptidase II from the fruit fly, Drosophila melanogaster. J. Biol. Chem. 273:1998;19173-19182.
26. Rock K.L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., Hwang D., Goldberg A.L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 78:1994;761-771.
27. Roelse J., Gromme M., Momburg F., Hammerling G., Neefjes J. Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J. Exp. Med. 180:1994;1591-1597.
28. Rose C., Vargas F., Facchinetti P., Bourgeat P., Bambal R.B., Bishop P.B., Chan S.M., Moore A.N., Ganellin C.R., Schwartz J.C. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature. 380:1996;403-409.
29. Saric T., Beninga J., Graef C.I., Akopian T.N., Rock K.L., Goldberg A.L. Major histocompatibility complex class I-presented antigenic peptides are degraded in cytosolic extracts primarily by thimet oligopeptidase. J. Biol. Chem. 276:2001;36474-36481.
30. Saric T., Chang S.C., Hattori A., York I.A., Markant S., Rock K.L., Tsujimoto M., Goldberg A.L. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat. Immunol. 3:2002;1169-1176.
31. Schubert U., Anton L.C., Gibbs J., Norbury C.C., Yewdell J.W., Bennink J.R. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 404:2000;770-774.
32. Seifert U., Maranon C., Shmueli A., Desoutter J.F., Wesoloski L., Janek K., Henklein P., Diescher S., Andrieu M., de la Salle H.et al. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat. Immunol. 4:2003;375-379.
33. Serwold T., Gonzalez F., Kim J., Jacob R., Shastri N. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature. 419:2002;480-483.
34. Stoltze L., Schirle M., Schwarz G., Schroter C., Thompson M.W., Hersh L.B., Kalbacher H., Stevanovic S., Rammensee H.G., Schild H. Two new proteases in the MHC class I processing pathway. Nat. Immunol. 1:2000;413-418.
35. Sugawara S., Abo T., Kumagai K. A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. J. Immunol. Methods. 100:1987;83-90.
36. Toes R.E., Nussbaum A.K., Degermann S., Schirle M., Emmerich N.P., Kraft M., Laplace C., Zwinderman A., Dick T.P., Muller J.et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med. 194:2001;1-12.
37. Tomkinson B. Tripeptidyl peptidases. enzymes that count Trends Biochem. Sci. 24:1999;355-359.
38. Turzynski A., Mentlein R. Prolyl aminopeptidase from rat brain and kidney. Action on peptides and identification as leucyl aminopeptidase. Eur. J. Biochem. 190:1990;509-515.
39. Yellen-Shaw A.J., Wherry E.J., Dubois G.C., Eisenlohr L.C. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. J. Immunol. 158:1997;3227-3234.
40. Yewdell J.W., Reits E., Neefjes J. Making sense of mass destruction. quantitating MHC class I antigen presentation Nat. Rev. Immunol. 3:2003;952-961.
41. York I.A., Chang S.C., Saric T., Keys J.A., Favreau J.M., Goldberg A.L., Rock K.L. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat. Immunol. 3:2002;1177-1184.
42. York I.A., Mo A.X., Lemerise K., Zeng W., Shen Y., Abraham C.R., Saric T., Goldberg A.L., Rock K.L. The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation. Immunity. 18:2003;429-440.